Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

I-TECH (Lim)
  NCT04920942		 RCTivermectincontrolCOVID-19 mild to moderatesome concern
241/249 inconclusive
  • inconclusive 25 % increase in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
Abd-Elsalam
  NCT04403555		 RCTivermectincontrolCOVID-19 mild to moderatehigh
82/82 inconclusive
    Bukhari
          NCT04392713    		 RCTivermectinstandard of careCOVID-19 mild to moderatehigh
    		50/50 suggested
    • suggested 10.6-fold increase in viral clearance by day 7 but with a low degree of certainty due to high risk of bias
    Kirti
          CTRI/2020/08/027225    		 RCTivermectinplaceboCOVID-19 mild to moderatesome concern
    		57/58 inconclusive
    • inconclusive 20 % decrease in viral clearance by day 7 (PE) with a moderate degree of certainty due to some concern in risk of bias
    RIVET-COV (Mohan) (12mg and 24mg)
          CTRI/2020/06/026001    		 RCTivermectinplaceboCOVID-19 mild to moderatehigh
    		104/52 inconclusive
    • inconclusive 10 % increase in viral clearance ,viral clearance by day 7 (PE) but with a low degree of certainty due to high risk of bias
    Ahmed RCTivermectinplaceboCOVID-19 mild to moderatehigh
    		48/24 suggested
    • suggested 3.1-fold increase in viral clearance (time to event analysis only),viral clearance by day 14 (PE) but with a low degree of certainty due to high risk of bias
    Paradoxically comparison of day 7 and 14 virological clearance between ivermectin doxycycline group vs placebo was not statistically significant (HR 2.3[0.6-9.0] and 1.7[0.8-4.0])
    Chaccour
          NCT04390022    		 RCTivermectinplaceboCOVID 19 outpatients, COVID-19 mild to moderatelow
    		12/12 inconclusive
    • inconclusive 8 % decrease in viral clearance ,viral clearance by day 7 (PE) with a high degree of certainty due to low risk of bias
    Chachar
          NCT04739410    		 RCTivermectinstandard of careCOVID-19 mild to moderatehigh
    		25/25 inconclusive
    • inconclusive 19 % increase in clinical improvement,clinical improvement (7-day) (PE) but with a low degree of certainty due to high risk of bias
    Krolewiecki
          NCT004381884    		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
    		30/15 inconclusive
      NCT04523831 (Mahmud)
              NCT04523831      		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
      		200/200 safety concern
      • suggested 89 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 93 % increase in clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 56 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
      • statistically significant 17.6-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
      Shahbaznejad
              IRCT20111224008507N3      		 RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
      		35/38 inconclusive
        3 studies excluded by filtering options (0 RCT / 3 OBS)

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

         

        - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons